These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Nejat&Sadr_Manuscripts_V2.pdf (3.17 MB)

Are Losartan and Imatinib Effective Against SARS-CoV2 Pathogenesis? a Pathophysiologic-Based in Silico Study

revised on 04.11.2020, 08:44 and posted on 04.11.2020, 09:01 by Reza Nejat, Ahmad Shahir Sadr
COVID19 has spread all over the globe with ARDS as the most grave complicating factor in its mortality and morbidity. As there is not an effective anti-viral drug or an imminent vaccine against this virus we proposed a novel insight about cytokine storm-indiced ARDS in this disease and conducted an in silico study according to the pathophysiology of cytokine storm. We found that losartan and imatinib may break the life cycle of the virus to the degree that its affinity to ACE2 may decline, the function of papin-like protease disrupts, and the cytokine storm may subside, as well. This means that the death toll of the disease may decline sharply till a vaccine is produced in the near future. All the results should be validated in subclinical studies.


No funder supported the authors


Email Address of Submitting Author


Shahid Beheshti University



ORCID For Submitting Author


Declaration of Conflict of Interest

No conflict of interest